LegDeb2 Global Registry for Use of Legflow in Peripheral Arteries

Inclusion Criteria: Age ≥ 18 years or minimum age as required by local regulations. * Subject with documented diagnosis of lower extremities arterial disease (LEAD). * Angiographically documented single or multiple lesions/occlusions (de novo or re-stenotic lesion(s) or in-stent restenosis within the target vessels with a minimum lesion length of 2 cm including bilateral disease if both limbs are treated within 35 days. * Positive diagnostic indication for PTA with a DEB in accordance with the Instructions For Use (IFU) of the Legflow DEB. * Adequate distal run-off to the ankle (at least one native calf vessel \[posterior tibial, anterior tibial, or peroneal arteries\] is patent, defined as ≤ 50% diameter stenosis) either pre-existing or successfully re- established prior to target lesion treatment. * Adequate inflow (≤ 50% diameter stenosis) either pre-existing or successfully re-established prior to target lesion treatment. * Female subjects of childbearing potential must have a negative pregnancy test ≤ 7 days before enrollment. * Signed and dated Patient Informed Consent (PIC) form. * Ability and willingness to comply with the clinical investigation plan (CIP). * Life expectancy, in the Investigator's opinion, of at least 12 months Exclusion Criteria: * High probability of non-adherence to CIP follow-up requirements. * Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion in the absence of flow limiting dissections or perforations). * Lesion within or adjacent to an aneurysm or presence of a popliteal aneurysm. * Acute or sub-acute thrombus in the target vessel. * Target lesion also requires treatment with alternative drug eluting technology-based therapy or other antiproliferative therapy (cryoplasty, brachytherapy). * Plan for surgical or interventional procedure within 30 days after the study procedure (except for bilateral target limb treatment). * Known allergies or sensitivities to heparin, aspirin, other anti- coagulant/anti-platelet therapies, and/or paclitaxel.